Partner Therapeutics Announces Publication of Clinical Trial Results of Leukine® (sargramostim) in Patients with Parkinson’s Disease

Immune transformation after intermittent dosing with Leukine shows promise for Parkinson’s disease

LEXINGTON, MA – May 19, 2021 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT03790670) evaluating the use of Leukine® (sargramostim, yeast-derived rhuGM-CSF) in patients with Parkinson’s Disease. Participants were evaluated for safety and tolerability as well as disease signs and symptoms including a standard Parkinson’s mobility test (Movement Disorder Society (MDS) – Unified ...

Continue Reading →